27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $345.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to ...
Fintel on MSN2d
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy Recommendation
Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Redburn Atlantic
Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report ...
Business Wire5d
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark ...
Nasdaq3d
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and ...
Alnylam Pharma (ALNY) Receives a Buy from Piper Sandler
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...
Alnylam price target raised to $345 from $300 at Stifel
Stifel raised the firm’s price target on Alnylam (ALNY) to $345 from $300 and keeps a Buy rating on the shares following the recent FDA ...
Zacks.com on MSN2d
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...